Form D · Biotechnology
VerImmune, Inc.
Bethesda, MD · CIK 0001903915
Offering snapshot reported Sep 25, 2024 · SEC filing
- Reported sold
- $4.5M Offering amount: $8M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $22.8K Reported outside-investor minimum
- First sale
- Aug 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2024 | Initial | $4,495,354 | No comparison | 6 | SEC filing |
| Mar 31, 2022 | Initial | $1,379,975 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-524908
Source: Form D, filed Sep 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Che Hsu | Director |
| Marta New | Director |
| Cynthia Poh | Director |
| Roger Pomerantz | Director |
| Kevin Koh Rongsheng | Director |
| Haolin Sung | Director |
| John Troyer | Executive |
| Joshua Wang | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7200 Wisconsin Ave Suite 500
Bethesda, MD, 20814
Bethesda, MD, 20814